APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiangiogenic Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antiangiogenic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025191 pages

Choose your research edition.

Industry ResearchAntiangiogenic Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiangiogenic Drugs Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Antiangiogenic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiangiogenic Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiangiogenic Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Antiangiogenic Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Antiangiogenic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antiangiogenic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antiangiogenic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antiangiogenic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antiangiogenic Drugs include Chia Tai Tianqing, Sanofi, Jiangsu Hengrui Pharmaceuticals, Simcere, Roche, Pfizer, Novartis, Janssen Biotech and Exelixis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antiangiogenic Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antiangiogenic Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antiangiogenic Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antiangiogenic Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Antiangiogenic Drugs Segment by Company

Chia Tai Tianqing

Sanofi

Jiangsu Hengrui Pharmaceuticals

Simcere

Roche

Pfizer

Novartis

Janssen Biotech

Exelixis

Eli Lilly

Eisai

Boehringer Ingelheim

Bayer

AstraZeneca

Antiangiogenic Drugs Segment by Type

Macromolecular Single-target Angiogenesis Inhibitor

Endogenous Pan-target Angiogenesis Inhibitor

Small Molecule Multi-target Angiogenesis Inhibitor

Antiangiogenic Drugs Segment by Application

Cancer Therapy

Inflammatory and Autoimmune Diseases

Ophthalmic Diseases

Other

Antiangiogenic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiangiogenic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiangiogenic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiangiogenic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antiangiogenic Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antiangiogenic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Antiangiogenic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Antiangiogenic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Antiangiogenic Drugs Industry Trends Table 2. Antiangiogenic Drugs Industry Drivers Table 3. Antiangiogenic Drugs Industry Opportunities and Challenges Table 4. Antiangiogenic Drugs Industry Restraints Table 5. Global Antiangiogenic Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Antiangiogenic Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Antiangiogenic Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Antiangiogenic Drugs Sales Market Share by Manufacturers Table 9. Global Antiangiogenic Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Antiangiogenic Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Antiangiogenic Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Antiangiogenic Drugs Manufacturers, Product Type & Application Table 13. Global Antiangiogenic Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Antiangiogenic Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Macromolecular Single-target Angiogenesis Inhibitor Table 17. Major Manufacturers of Endogenous Pan-target Angiogenesis Inhibitor Table 18. Major Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor Table 19. Global Antiangiogenic Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Antiangiogenic Drugs Sales by Type (2021-2026) & (K Units) Table 21. Global Antiangiogenic Drugs Sales by Type (2027-2032) & (K Units) Table 22. Global Antiangiogenic Drugs Sales Market Share by Type (2021-2026) Table 23. Global Antiangiogenic Drugs Sales Market Share by Type (2027-2032) Table 24. Global Antiangiogenic Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Antiangiogenic Drugs Revenue by Type (2021-2026) & (K Units) Table 26. Global Antiangiogenic Drugs Revenue by Type (2027-2032) & (K Units) Table 27. Global Antiangiogenic Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Antiangiogenic Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Cancer Therapy Table 30. Major Manufacturers of Inflammatory and Autoimmune Diseases Table 31. Major Manufacturers of Ophthalmic Diseases Table 32. Major Manufacturers of Other Table 33. Global Antiangiogenic Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Antiangiogenic Drugs Sales by Application (2021-2026) & (K Units) Table 35. Global Antiangiogenic Drugs Sales by Application (2027-2032) & (K Units) Table 36. Global Antiangiogenic Drugs Sales Market Share by Application (2021-2026) Table 37. Global Antiangiogenic Drugs Sales Market Share by Application (2027-2032) Table 38. Global Antiangiogenic Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Antiangiogenic Drugs Revenue by Application (2021-2026) & (K Units) Table 40. Global Antiangiogenic Drugs Revenue by Application (2027-2032) & (K Units) Table 41. Global Antiangiogenic Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Antiangiogenic Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Antiangiogenic Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Antiangiogenic Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Antiangiogenic Drugs Sales Market Share by Region (2021-2026) Table 46. Global Antiangiogenic Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Antiangiogenic Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Antiangiogenic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Antiangiogenic Drugs Sales by Country (2021-2026) & (K Units) Table 50. North America Antiangiogenic Drugs Sales by Country (2027-2032) & (K Units) Table 51. Europe Antiangiogenic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Antiangiogenic Drugs Sales by Country (2021-2026) & (K Units) Table 53. Europe Antiangiogenic Drugs Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Antiangiogenic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Antiangiogenic Drugs Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Antiangiogenic Drugs Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Antiangiogenic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Antiangiogenic Drugs Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Antiangiogenic Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Antiangiogenic Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Antiangiogenic Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Antiangiogenic Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Antiangiogenic Drugs Revenue Market Share by Region (2027-2032) Table 65. Chia Tai Tianqing Company Information Table 66. Chia Tai Tianqing Business Overview Table 67. Chia Tai Tianqing Antiangiogenic Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Chia Tai Tianqing Antiangiogenic Drugs Product Portfolio Table 69. Chia Tai Tianqing Recent Development Table 70. Sanofi Company Information Table 71. Sanofi Business Overview Table 72. Sanofi Antiangiogenic Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sanofi Antiangiogenic Drugs Product Portfolio Table 74. Sanofi Recent Development Table 75. Jiangsu Hengrui Pharmaceuticals Company Information Table 76. Jiangsu Hengrui Pharmaceuticals Business Overview Table 77. Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product Portfolio Table 79. Jiangsu Hengrui Pharmaceuticals Recent Development Table 80. Simcere Company Information Table 81. Simcere Business Overview Table 82. Simcere Antiangiogenic Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Simcere Antiangiogenic Drugs Product Portfolio Table 84. Simcere Recent Development Table 85. Roche Company Information Table 86. Roche Business Overview Table 87. Roche Antiangiogenic Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Roche Antiangiogenic Drugs Product Portfolio Table 89. Roche Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer Antiangiogenic Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Pfizer Antiangiogenic Drugs Product Portfolio Table 94. Pfizer Recent Development Table 95. Novartis Company Information Table 96. Novartis Business Overview Table 97. Novartis Antiangiogenic Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Novartis Antiangiogenic Drugs Product Portfolio Table 99. Novartis Recent Development Table 100. Janssen Biotech Company Information Table 101. Janssen Biotech Business Overview Table 102. Janssen Biotech Antiangiogenic Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Janssen Biotech Antiangiogenic Drugs Product Portfolio Table 104. Janssen Biotech Recent Development Table 105. Exelixis Company Information Table 106. Exelixis Business Overview Table 107. Exelixis Antiangiogenic Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Exelixis Antiangiogenic Drugs Product Portfolio Table 109. Exelixis Recent Development Table 110. Eli Lilly Company Information Table 111. Eli Lilly Business Overview Table 112. Eli Lilly Antiangiogenic Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Eli Lilly Antiangiogenic Drugs Product Portfolio Table 114. Eli Lilly Recent Development Table 115. Eisai Company Information Table 116. Eisai Business Overview Table 117. Eisai Antiangiogenic Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Eisai Antiangiogenic Drugs Product Portfolio Table 119. Eisai Recent Development Table 120. Boehringer Ingelheim Company Information Table 121. Boehringer Ingelheim Business Overview Table 122. Boehringer Ingelheim Antiangiogenic Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Boehringer Ingelheim Antiangiogenic Drugs Product Portfolio Table 124. Boehringer Ingelheim Recent Development Table 125. Bayer Company Information Table 126. Bayer Business Overview Table 127. Bayer Antiangiogenic Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Bayer Antiangiogenic Drugs Product Portfolio Table 129. Bayer Recent Development Table 130. AstraZeneca Company Information Table 131. AstraZeneca Business Overview Table 132. AstraZeneca Antiangiogenic Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. AstraZeneca Antiangiogenic Drugs Product Portfolio Table 134. AstraZeneca Recent Development Table 135. Key Raw Materials Table 136. Raw Materials Key Suppliers Table 137. Antiangiogenic Drugs Distributors List Table 138. Antiangiogenic Drugs Customers List Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Antiangiogenic Drugs Product Image Figure 2. Global Antiangiogenic Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiangiogenic Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Antiangiogenic Drugs Sales (2021-2032) & (K Units) Figure 5. Global Antiangiogenic Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Antiangiogenic Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Macromolecular Single-target Angiogenesis Inhibitor Image Figure 9. Endogenous Pan-target Angiogenesis Inhibitor Image Figure 10. Small Molecule Multi-target Angiogenesis Inhibitor Image Figure 11. Global Antiangiogenic Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Antiangiogenic Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Antiangiogenic Drugs Sales Market Share by Type (2021-2032) Figure 14. Global Antiangiogenic Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Antiangiogenic Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Antiangiogenic Drugs Revenue Market Share by Type (2021-2032) Figure 17. Cancer Therapy Image Figure 18. Inflammatory and Autoimmune Diseases Image Figure 19. Ophthalmic Diseases Image Figure 20. Other Image Figure 21. Global Antiangiogenic Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Antiangiogenic Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Antiangiogenic Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Antiangiogenic Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Antiangiogenic Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Antiangiogenic Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Antiangiogenic Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Antiangiogenic Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Antiangiogenic Drugs Sales Market Share by Country (2021-2032) Figure 41. China Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Antiangiogenic Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Antiangiogenic Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Antiangiogenic Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Antiangiogenic Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Antiangiogenic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Antiangiogenic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Antiangiogenic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Antiangiogenic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Antiangiogenic Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Antiangiogenic Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Macromolecular Single-target Angiogenesis Inhibitor
  • Endogenous Pan-target Angiogenesis Inhibitor
  • Small Molecule Multi-target Angiogenesis Inhibitor
Applications
  • Cancer Therapy
  • Inflammatory and Autoimmune Diseases
  • Ophthalmic Diseases
  • Other
Companies covered
  • Chia Tai Tianqing
  • Sanofi
  • Jiangsu Hengrui Pharmaceuticals
  • Simcere
  • Roche
  • Pfizer
  • Novartis
  • Janssen Biotech
  • Exelixis
  • Eli Lilly
  • Eisai
  • Boehringer Ingelheim
  • Bayer
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antiangiogenic Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antiangiogenic Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Antiangiogenic Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Antiangiogenic Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Antiangiogenic Drugs Market Dynamics
  1. 2.1 Antiangiogenic Drugs Industry Trends
  2. 2.2 Antiangiogenic Drugs Industry Drivers
  3. 2.3 Antiangiogenic Drugs Industry Opportunities and Challenges
  4. 2.4 Antiangiogenic Drugs Industry Restraints
3 Antiangiogenic Drugs Market by Manufacturers
  1. 3.1 Global Antiangiogenic Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Antiangiogenic Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Antiangiogenic Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Antiangiogenic Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antiangiogenic Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Antiangiogenic Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Antiangiogenic Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antiangiogenic Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antiangiogenic Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antiangiogenic Drugs Tier 1, Tier 2, and Tier 3
4 Antiangiogenic Drugs Market by Type
  1. 4.1 Antiangiogenic Drugs Type Introduction
  2. 4.1.1 Macromolecular Single-target Angiogenesis Inhibitor
  3. 4.1.2 Endogenous Pan-target Angiogenesis Inhibitor
  4. 4.1.3 Small Molecule Multi-target Angiogenesis Inhibitor
  5. 4.2 Global Antiangiogenic Drugs Sales by Type
  6. 4.2.1 Global Antiangiogenic Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Antiangiogenic Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global Antiangiogenic Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Antiangiogenic Drugs Revenue by Type
  10. 4.3.1 Global Antiangiogenic Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Antiangiogenic Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global Antiangiogenic Drugs Revenue Market Share by Type (2021-2032)
5 Antiangiogenic Drugs Market by Application
  1. 5.1 Antiangiogenic Drugs Application Introduction
  2. 5.1.1 Cancer Therapy
  3. 5.1.2 Inflammatory and Autoimmune Diseases
  4. 5.1.3 Ophthalmic Diseases
  5. 5.1.4 Other
  6. 5.2 Global Antiangiogenic Drugs Sales by Application
  7. 5.2.1 Global Antiangiogenic Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Antiangiogenic Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Antiangiogenic Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Antiangiogenic Drugs Revenue by Application
  11. 5.3.1 Global Antiangiogenic Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Antiangiogenic Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Antiangiogenic Drugs Revenue Market Share by Application (2021-2032)
6 Global Antiangiogenic Drugs Sales by Region
  1. 6.1 Global Antiangiogenic Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antiangiogenic Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Antiangiogenic Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Antiangiogenic Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antiangiogenic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Antiangiogenic Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Antiangiogenic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Antiangiogenic Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Antiangiogenic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Antiangiogenic Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Antiangiogenic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Antiangiogenic Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Antiangiogenic Drugs Revenue by Region
  1. 7.1 Global Antiangiogenic Drugs Revenue by Region
  2. 7.1.1 Global Antiangiogenic Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Antiangiogenic Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Antiangiogenic Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Antiangiogenic Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Antiangiogenic Drugs Revenue (2021-2032)
  8. 7.2.2 North America Antiangiogenic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Antiangiogenic Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Antiangiogenic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Antiangiogenic Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Antiangiogenic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Antiangiogenic Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Antiangiogenic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing
  2. 8.1.1 Chia Tai Tianqing Company Information
  3. 8.1.2 Chia Tai Tianqing Business Overview
  4. 8.1.3 Chia Tai Tianqing Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Antiangiogenic Drugs Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Antiangiogenic Drugs Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Jiangsu Hengrui Pharmaceuticals
  14. 8.3.1 Jiangsu Hengrui Pharmaceuticals Company Information
  15. 8.3.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  16. 8.3.3 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product Portfolio
  18. 8.3.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  19. 8.4 Simcere
  20. 8.4.1 Simcere Company Information
  21. 8.4.2 Simcere Business Overview
  22. 8.4.3 Simcere Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Simcere Antiangiogenic Drugs Product Portfolio
  24. 8.4.5 Simcere Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Antiangiogenic Drugs Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Antiangiogenic Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis Antiangiogenic Drugs Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Janssen Biotech
  44. 8.8.1 Janssen Biotech Company Information
  45. 8.8.2 Janssen Biotech Business Overview
  46. 8.8.3 Janssen Biotech Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Janssen Biotech Antiangiogenic Drugs Product Portfolio
  48. 8.8.5 Janssen Biotech Recent Developments
  49. 8.9 Exelixis
  50. 8.9.1 Exelixis Company Information
  51. 8.9.2 Exelixis Business Overview
  52. 8.9.3 Exelixis Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Exelixis Antiangiogenic Drugs Product Portfolio
  54. 8.9.5 Exelixis Recent Developments
  55. 8.10 Eli Lilly
  56. 8.10.1 Eli Lilly Company Information
  57. 8.10.2 Eli Lilly Business Overview
  58. 8.10.3 Eli Lilly Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly Antiangiogenic Drugs Product Portfolio
  60. 8.10.5 Eli Lilly Recent Developments
  61. 8.11 Eisai
  62. 8.11.1 Eisai Company Information
  63. 8.11.2 Eisai Business Overview
  64. 8.11.3 Eisai Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Eisai Antiangiogenic Drugs Product Portfolio
  66. 8.11.5 Eisai Recent Developments
  67. 8.12 Boehringer Ingelheim
  68. 8.12.1 Boehringer Ingelheim Company Information
  69. 8.12.2 Boehringer Ingelheim Business Overview
  70. 8.12.3 Boehringer Ingelheim Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Boehringer Ingelheim Antiangiogenic Drugs Product Portfolio
  72. 8.12.5 Boehringer Ingelheim Recent Developments
  73. 8.13 Bayer
  74. 8.13.1 Bayer Company Information
  75. 8.13.2 Bayer Business Overview
  76. 8.13.3 Bayer Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bayer Antiangiogenic Drugs Product Portfolio
  78. 8.13.5 Bayer Recent Developments
  79. 8.14 AstraZeneca
  80. 8.14.1 AstraZeneca Company Information
  81. 8.14.2 AstraZeneca Business Overview
  82. 8.14.3 AstraZeneca Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AstraZeneca Antiangiogenic Drugs Product Portfolio
  84. 8.14.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antiangiogenic Drugs Value Chain Analysis
  2. 9.1.1 Antiangiogenic Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antiangiogenic Drugs Production Mode & Process
  6. 9.2 Antiangiogenic Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antiangiogenic Drugs Distributors
  9. 9.2.3 Antiangiogenic Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst